Nexien BioPharma, Inc.

NXEN

US65343D1000

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 02:30:12 2024-04-26 pm EDT			5-day change	1st Jan Change
0.0168 ^USD	-17.04%		-42.07%	-35.14%

Feb. 20	Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023

November 14, 2023 at 05:01 pm EST

Nexien BioPharma, Inc. reported earnings results for the first quarter ended September 30, 2023. For the first quarter, the company reported net loss was USD 0.074918 million compared to USD 0.094874 million a year ago. Basic loss per share from continuing operations was USD 0.001 compared to USD 0.002 a year ago.

Latest news about Nexien BioPharma, Inc.

Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 20	CI
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-28	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-17	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-08	CI
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-09	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-09-28	CI
Nexien BioPharma, Inc. Auditor Raises 'Going Concern' Doubt	22-09-27	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-05-12	CI
Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-08	CI
Nexien BioPharma, Inc. announced that it has received $0.15 million in funding from Quick Capital, LLC	22-01-17	CI
Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	21-11-22	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021	21-10-12	CI
Nexien BioPharma, Inc. Auditor Raises 'Going Concern' Doubt	21-10-11	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2021	21-05-05	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2020	21-02-11	CI
Nexien Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2020	20-11-10	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2020	20-09-28	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2020	20-05-14	CI
Nexien BioPharma, Inc. Announces Management Changes	20-04-06	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2019	20-02-12	CI
Nexien Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2019	19-11-12	CI
Nexien BioPharma, Inc. Announces Resignation of Courtney Clark from Director	19-10-22	CI
Intiva Biopharma Inc. Reports Earnings Results for the Full Year Ended June 30, 2019	19-09-30	CI
Nexien Biopharma, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2019	19-05-14	CI

Chart Nexien BioPharma, Inc.

Duration

Period

More charts

Company Profile

Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NEXIEN BIOPHARMA, INC.	-35.14%	1.13M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B